Lynette M. Sholl

<i>STK11/LKB1</i> Mutations and PD-1 Inhibitor Resistance in <i>KRAS</i>-Mutant Lung Adenocarcinoma

Ferdinandos Skoulidis, Michael E. Goldberg, Danielle Greenawalt et al. · Cancer Discovery · 2018 · 1.6K citations · Full text

Medicine, Oncology, Pharmacology +16

Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors

Esra A. Akbay, Shohei Koyama, Julián Carretero et al. · Cancer Discovery · 2013 · 1.2K citations · Full text

Medicine, Immunology, Oncology +17

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology

Neal I. Lindeman, Philip T. Cagle, Dara L. Aisner et al. · Archives of Pathology & Laboratory Medicine · 2018 · 931 citations · Full text

Medicine, Oncology, Pathology +17

Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors

Diana Miao, Claire A. Margolis, Natalie I. Vokes et al. · Nature Genetics · 2018 · 696 citations · Full text

Medicine, Genetics, Oncology +16

Assessment of Resistance Mechanisms and Clinical Implications in Patients With<i>EGFR</i>T790M–Positive Lung Cancer and Acquired Resistance to Osimertinib

Geoffrey R. Oxnard, Yuebi Hu, Kathryn F. Mileham et al. · JAMA Oncology · 2018 · 689 citations · Full text

Medicine, Oncology, Pharmacology +17